1) What is Salesforce?

Salesforce is the world’s leading customer relationship management (CRM) platform, helping organizations connect with their customers in entirely new ways. For over a decade, Salesforce has built industry-specific solutions designed to meet the unique nuances of every business sector. In Life Sciences, Salesforce isdeeply committed and invested in empowering pharmaceutical, biotech, and medtech companies to deliver more personalized, connected experiences – from clinical development through commercialization—by uniting data, AI, and trusted relationships on a single platform.

2) What about Salesforce’s work and impact makes you the most proud?

What makes me most proud is seeing how our technology helps bring life-changing treatments and devices to patients faster and with more empathy. Every improvement we make, whether it’s enhancing trial engagement, enabling field teams to better support healthcare professionals, or helping manufacturers deliver vital therapies efficiently – ultimately reaches the patient. Knowing that our work helps people access care sooner, participate more easily in their health journey, and live healthier, fuller lives is what truly drives me.

3) What is on the horizon for Salesforce? What is something exciting people can expect to see from the organization in the near future?

Life Sciences at Salesforce is entering an incredibly exciting chapter. We recently launched Agentforce Life Sciences for Customer Engagement, our end-to-end engagement platform designed to unite every stakeholder – across marketing, service, medical, key account management, and sales – on a single, intelligent platform. By connecting all data sources and orchestrating personalized experiences across channels, we’re empowering teams with actionable insights that were previously out of reach. We’ve created an entire agentic system of action that is going to transform the future of life sciences.

4) Tell us about your professional journey in the life sciences industry. How did you first get involved and what were some of the key moments that led you to working at Salesforce?

My journey in the life sciences industry began somewhat serendipitously. In 2008, after nearly eight years at Salesforce, I joined Veeva Systems during its very first year to build and lead the professional services organization. It was an incredible opportunity to help shape a company that would go on to transform how the BioPharma industry engages with technology. Over the course of 16 years at Veeva, I held several executive roles and had the privilege of leading the team that implemented

 Veeva CRM across much of the BioPharma industry; a formative experience that deepened my understanding of both the technology and the evolving needs of our customers. In my final two years, I served as General Manager of Vault CRM; a role that provided a front-row seat to the shifts occurring in the industry; especially the growing demand for more intelligent, connected, and adaptable solutions. Around that time, early 2023, the emergence of generative AI felt truly transformative. I quickly recognized the immense potential AI holds for life sciences, and I saw that Salesforce not only had world-class AI technology and expertise but also a commitment to the industry. When Salesforce’s Life Sciences partner decided to end their collaboration, it created a unique and timely opportunity to return to Salesforce and help lead this next era of innovation for the industry that I am very excited about.

5) What’s the biggest challenge you’ve faced as a leader and how did you navigate it?

We are truly at a pivotal moment – standing at the intersection of rapid industry change, the rise of AI, and an evolving software landscape that underpins the life sciences sector. Leading Life Sciences at Salesforce in such a dynamic and competitive environment requires careful balance: bringing to life the innovations possible today while recognizing that this is a risk-averse industry, often slower to move away from legacy technology. Life sciences was one of the last industries to fully embrace the cloud, so navigating today’s transformation feels reminiscent of those early days of cloud adoption. It demands both patience and persistence, along with a clear vision for how emerging technologies like AI can drive meaningful impact – all while respecting the unique pace and regulatory complexity of the industry.

6) What advice would you give to aspiring life sciences leaders who are looking to make a lasting impact?

I talk to life sciences leaders all the time who say, “It’s just too much right now.” And I get it – the pace of innovation can feel relentless. But transformation doesn’t happen overnight. You have to start somewhere. Take a pragmatic approach: focus on the outcomes you want to achieve, start with manageable steps, and keep learning along the way. The future won’t wait for anyone to catch up, so the best thing you can do is simply begin. Those leaders who take the leap are often the ones I see making the most lasting impact.

7) Outside of your career, what are some of the favorite ways to spend your time?

Well, if you know this market and what’s currently happening; you’d know that finding time outside of work can be challenging. But I’m a single dad of three great and very active kids; from driving to practices; to flying to tournaments and college visits; I get to see my kids discover what brings them joy; and encouraging that is an incredibly rewarding experience. Outside of family time; I try to watch or attend as many Golden State Warriors games as I can; or get on the water; cruising around the Bay or going fishing.

8) What do you appreciate most about being part of the Medical Alley community?

Medical Alley is one of the few places where you see real cross-industry learning in action. You have medtech pioneers, biopharma innovators, payers, providers, and tech companies all at the same table. That mix of perspectives sparks creativity and helps us think differently about how we deliver better outcomes together.

9) How do you see the life sciences industry evolving over the next 5-10 years?

The next five to ten years will mark the rise of the agentic enterprise – organizations that use AI and automation not just to analyze but to act. For life sciences, that means breakthroughs in precision medicine, accelerated development timelines, and deeply personalized patient experiences. This agentic era is about elevating humans through digital labor; freeing researchers, clinicians, and field teams from repetitive tasks so they can focus on innovation, relationships, and the patient experience. At the same time, we’ll see a major shift toward direct-to-patient and direct-to-consumer engagement. As data, digital platforms, and connected devices converge, patients will become active participants rather than passive recipients of care – managing their conditions, accessing therapies, and engaging with manufacturers more directly than ever before. AI won’t replace people, it will amplify their impact, empowering a more connected, transparent, and patient-driven life sciences ecosystem.

10) How can the Medical Alley community rise to face those changes and challenges?

To embrace the agentic era, start by building awareness of AI and its potential, and identify areas where it can have the most impact as well as areas of security risk. Invest in reskilling your workforce so people can work effectively alongside emerging technologies. Pick a trusted partner to help guide and lead the transformation, providing expertise, structure, cyber-security, and support. Encourage collaboration through cross-functional teams, partnerships, and shared learning. Pilot new projects carefully, establish clear ethical guidelines, and iterate based on results. By balancing experimentation with responsibility, you can innovate, adapt, and lead in this new era.